EMA Authorised: Aspaveli (pegcetacoplan) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

Aspaveli (pegcetacoplan) by Swedish Orphan Biovitrum AB has been authorised by the EMA for paroxysmal nocturnal hemoglobinuria (PNH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Aspaveli (pegcetacoplan)

Snippet

Status: Authorised. Therapeutic area: Hemoglobinuria, Paroxysmal. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 20/07/2026. Orphan medicine